Open trial of milnacipran for Taijin-Kyofusho in Japanese patients with social anxiety disorder
Open trial of milnacipran for Taijin-Kyofusho in Japanese patients with social anxiety disorder
复制标题
米那普仑在日本社交焦虑障碍患者中进行 Taijin-Kyofusho 的公开试验
DOI：
10.1080/13651500310000690
复制
发表时间：
2003
影响因子：
3
通讯作者：
T. Iketani
中科院分区：
文献类型：
--
作者：
N. Kiriike;T. Nagata;J. Oshima;Akira Wada;H. Yamada;T. Iketani
摘要目的：Taijin-Kyofusho （TKS）被认为是日本文化特有的一种独特形式的社交焦虑障碍，患者强烈恐惧自己的身体或其功能冒犯他人；尽管此前日本专家坚持认为，“攻击性”型TKS和典型型TKS（类似于西方国家的社交焦虑症）不能分开考虑。选择性5 -羟色胺再摄取抑制剂，以及最近的5 -羟色胺和去甲肾上腺素再摄取抑制剂（SNRI）已被证明对治疗社交焦虑症有效。然而，SNRI在TKS中的疗效尚未得到评估。方法：本研究是一项为期12周的SNRI， milnacipran （Toledomin®，Ixel®）在12例攻击性TKS患者中的开放试验（如果DSM-IV诊断标准扩大，也伴有社交焦虑症）。TKS的诊断标准和TKS严重程度量表是从日本文献中描述的症状学发展而来的。反应的主要标准是临床总体印象（CGI）的改善。采用TKS攻击性焦虑量表（0-3）、Liebowitz社交焦虑量表（LSAS）、Sheehan残疾量表和若干份自我报告问卷。结果：完成治疗的11例患者中有6例有反应（CGI“改善很大”或“非常改善”）。LSAS平均得分和TKS攻击性焦虑均有统计学显著降低。结论：SNRI类药物milnacpran对TKS有一定的治疗作用。milnacpran在TKS中的进一步研究似乎是有必要的。
Abstract OBJECTIVE: Taijin-Kyofusho (TKS) is thought to be a distinct form of social anxiety disorder specific to Japanese culture in which the patient suffers from intense fear that his or her body or its functions are offensive to other people; although previously Japanese experts have insisted that the" offensive" type of TKS and the typical type (which is similar to social anxiety disorder in Western countries) could not be considered separately. Selective serotonin reuptake inhibitors, and more recently serotonin and noradrenaline reuptake inhibitors (SNRI), have been shown to be effective in treating social anxiety disorders. However, the efficacy of SNRI has not yet been assessed in TKS. METHODS: The present study was a 12-week open trial of the SNRI, milnacipran (Toledomin®, Ixel®) in 12 patients with offensive type of TKS (also with social anxiety disorder, if DSM-IV diagnostic criteria were expanded). Diagnostic criteria of TKS and a TKS severity scale were developed from the symptomatology described in the Japanese literature. The primary criterion for response was improvement on the Clinical Global Impression (CGI). TKS offensive anxiety scale (0-3), the Liebowitz Social Anxiety Scale (LSAS), the Sheehan Disability Scale, and several self-reporting questionnaires were also used. RESULTS: Six of the 11 patients completing therapy responded (" much improved" or" very much improved" on CGI). The mean LSAS score and TKS offensive anxiety showed statistically significant reductions. CONCLUSION: The results suggest that the SNRI, milnacipran, may be helpful in the treatment of TKS. Further studies with milnacipran in TKS appear warranted.